However, a few studies indicated that higher baseline sPD-L1 levels were associated with the better treatment response or the longer PFS and OS in patients with cancer, such as lymphoma, [27] metastatic ccRCC, [74] and NSCLC [125]. Here, SPDL1 is linked to non-small cell lung carcinoma.